Beximco Pharmagdr Regs Stock Price To Sales
| R2WA Stock | EUR 0.41 0.00 0.00% |
BEXIMCO PHARMAGDR REGS fundamentals help investors to digest information that contributes to BEXIMCO PHARMAGDR's financial success or failures. It also enables traders to predict the movement of BEXIMCO Stock. The fundamental analysis module provides a way to measure BEXIMCO PHARMAGDR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BEXIMCO PHARMAGDR stock.
BEXIMCO |
BEXIMCO PHARMAGDR REGS Company Price To Sales Analysis
BEXIMCO PHARMAGDR's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, BEXIMCO PHARMAGDR REGS has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-Specialty & Generic (which currently averages 0.0) industry. The price to sales for all Germany stocks is 100.0% higher than that of the company.
BEXIMCO Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BEXIMCO PHARMAGDR's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BEXIMCO PHARMAGDR could also be used in its relative valuation, which is a method of valuing BEXIMCO PHARMAGDR by comparing valuation metrics of similar companies.BEXIMCO PHARMAGDR is currently under evaluation in price to sales category among its peers.
BEXIMCO Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.14 % | |||
| Shares Outstanding | 446.11 M | |||
| Shares Owned By Institutions | 2.09 % | |||
| Gross Profit | 15.71 B | |||
| Debt To Equity | 27.50 % | |||
| Current Ratio | 2.26 X | |||
| Earnings Per Share | 0.10 X | |||
| Number Of Employees | 5.5 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 563.15 M | |||
| Annual Yield | 0.06 % |
About BEXIMCO PHARMAGDR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BEXIMCO PHARMAGDR REGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BEXIMCO PHARMAGDR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BEXIMCO PHARMAGDR REGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BEXIMCO Stock
BEXIMCO PHARMAGDR financial ratios help investors to determine whether BEXIMCO Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BEXIMCO with respect to the benefits of owning BEXIMCO PHARMAGDR security.